

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

APOTEX, INC.,

Petitioner,

v.

CELGENE CORPORATION,

Patent Owner.

---

Case IPR2023-00512

Patent 8,846,628

---

**DECLARATION OF NORA Q.E. PASSAMANECK IN SUPPORT OF  
UNOPPOSED MOTION FOR ADMISSION *PRO HAC VICE***

CELGENE 2153  
APOTEX v. CELGENE

I, Nora Q.E. Passamaneck, declare as follows:

1. I obtained a B.A. from New York University in 1998 and a J.D. from the Boston University School of Law in 2003.

2. I am currently a partner in the law firm of Wilmer Cutler Pickering Hale and Dorr LLP. I was admitted to the Massachusetts Bar in February 2004, the New York Bar in October 2004, and the Colorado Bar in February 2016. I have been practicing law for over 15 years. My practice has focused primarily on patent litigation. Over the course of my career, I have been counsel in numerous patent litigations.

3. I am a member in good standing of the Bars of the Commonwealth of Massachusetts, State of New York, and State of Colorado. I am admitted to practice before the U.S. District Courts for the District of Colorado, District Court for the Eastern District of New York, and District Court for the Southern District of New York. I am also admitted to practice before the U.S. Court of Appeals for the Federal Circuit and the Tenth Circuit.

4. My Massachusetts Bar membership number is 657723. My New York Bar membership number is 4262028. My Colorado Bar membership number is 49362.

5. I have assisted in a number of IPR proceedings, including *Pfizer Inc. et al. v. Genentech Inc.*, IPR2017-01121; *Celltrion Inc. v. Genentech Inc.*,

IPR2017-01122; *Hospira Inc. v. Genentech Inc.*, IPR2017-00731; and *Hospira Inc. et al. v. Genentech Inc.*, IPR2017-00737.

6. I have an established familiarity with the subject matter of U.S. Patent No. 8,846,628 (the '628 patent), the '628 patent's file history, and the prior art at issue in this proceeding. I am familiar with pharmaceutical technologies as a result of participation as counsel in related district court litigations on the '628 patent as well as prior pharmaceutical-related intellectual property cases on behalf of Bristol-Myers Squibb Co. I have also represented other pharmaceutical companies in intellectual property matters before federal district courts.

7. I have never been suspended or disbarred from practice before any court or administrative body.

8. I have never had a court or administrative body deny my application for admission to practice.

9. I have never had any sanctions or contempt citations imposed on me by any court or administrative body.

10. I attest to each of the listed items required by the Order – Notice of Filing Date Accorded to Petition And Time For Filing Patent Owner Preliminary Response in IPR2023-00512.

11. I have read and will comply with Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.

12. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Dated: October 18, 2023

Respectfully submitted,

/Nora Q.E. Passamaneck/  
Nora Q.E. Passamaneck  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
1225 Seventeenth Street  
Suite 2600  
Denver, CO, 80202  
Nora.Passamaneck@wilmerhale.com  
Tel.: 720-274-3152  
Fax: 720-274-3133